Jan 11, 2024 / 04:15PM GMT
Brian Cheng JPMorgan Chase&Co.-Analyst
Good morning, everyone. Thanks for joining us for a session at the 42nd JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here. I'm joined by my associates, John Kim, who is also in the audience. Up next, we have Zymeworks. We will be starting with a presentation by CEO, Ken Galbraith.
Ken, the stage is yours.
Ken Galbraith Zymeworks Inc.-Chair&CEO
That's great. Thank you very much. Thank you for the opportunity to present today on Thursday at JPMorgan. Welcome, everyone. Thank you for attending.
Just before I get started, I just want to reflect on a year ago being on this stage, also on Thursday, right after two really important events in the company's history. One, being the first pivotal study readout for zanidatamab in second-line biliary tract cancer, which was in December right before we came to the conference, which showed some very compelling data for zanidatamab and still the potential to be the first HER2
Zymeworks Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers